vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2019-4-20-25vtio-1102Research ArticleТРАНСПЛАНТАЦИЯ ОРГАНОВORGAN TRANSPLANTATIONЗлокачественные новообразования внепеченочной локализации после трансплантации печени: опыт одного трансплантационного центраExtrahepatic malignant neoplasms after liver transplantation: the experience of a single transplant centerГерасимоваО. А.GerasimovaO. A.

Герасимова Ольга Анатольевна

197758, Санкт-Петербург, п. Песочный, ул. Ленинградская, 70Тел. (812) 439-66-40 

Gerasimova Olga Anatolievna

70, Leningradskaya str., p. Pesochnyy, St-Petersburg, 197758Теl. (812) 439-66-40 

ren321@mail.ruБоровикВ. В.BorovikV. V.

Санкт-Петербург

St. Petersburg

ЖеребцовФ. К.ZherebtsovF. K.

Санкт-Петербург

St. Petersburg

ГрановД. А.GranovD. A.

Санкт-Петербург

St. Petersburg

ФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава РФ; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияGranov Russian Research Center of Radiology and Surgical Technologies; Saint-Petersburg State UniversityRussian FederationФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава РФРоссияGranov Russian Research Center of Radiology and Surgical TechnologiesRussian Federation2019310120202142025Copyright © Герасимова О.А., Боровик В.В., Жеребцов Ф.К., Гранов Д.А., 20202020Герасимова О.А., Боровик В.В., Жеребцов Ф.К., Гранов Д.А.Gerasimova O.A., Borovik V.V., Zherebtsov F.K., Granov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1102трансплантация печениde novo злокачественные новообразованиятакролимусэверолимусliver transplantationde novo malignant neoplasmsincidencetacrolimuseverolimusReferencesТрансплантация печени. Национальные клинические рекомендации. 2016 г. http://transpl.ru/files/rto/transpl_pecheni.pdf.Трансплантация печени. Национальные клинические рекомендации. 2016 г. http://transpl.ru/files/rto/transpl_pecheni.pdf.Liu ZN, Wang WT, Yan LN. Liver Surgery Group. De novo malignancies after liver transplantation with 14 cases at a single center. Transplant Proc. 2015; 47 (8): 2483–2487. doi: 10.1016/j.transproceed.2015.08.008.Liu ZN, Wang WT, Yan LN. Liver Surgery Group. De novo malignancies after liver transplantation with 14 cases at a single center. Transplant Proc. 2015; 47 (8): 2483–2487. doi: 10.1016/j.transproceed.2015.08.008.Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7 (9): 811–815. doi: 10.1053/jlts.2001.27084.Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001; 7 (9): 811–815. doi: 10.1053/jlts.2001.27084.Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001; 7 (11 Suppl 1): 109–118. doi: 10.1053/jlts.2001.28645.Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001; 7 (11 Suppl 1): 109–118. doi: 10.1053/jlts.2001.28645.Pillai AA. Management of de novo malignancies after liver transplantation. Transplant Rev (Orlando). 2015; 29 (1): 38–41. doi: 10.1016/j.trre.2014.11.002.Pillai AA. Management of de novo malignancies after liver transplantation. Transplant Rev (Orlando). 2015; 29 (1): 38–41. doi: 10.1016/j.trre.2014.11.002.Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306 (17): 1891–1901. doi: 10.1001/jama.2011.1592.Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306 (17): 1891–1901. doi: 10.1001/jama.2011.1592.Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009; 15, Suppl 2: 90–94. doi: 10.1002/lt.21898.Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009; 15, Suppl 2: 90–94. doi: 10.1002/lt.21898.Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10 (8): 1889–1896. doi: 10.1111/j.1600-6143.2010.03181.x.Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10 (8): 1889–1896. doi: 10.1111/j.1600-6143.2010.03181.x.Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2011; 29 (3): 707–714. doi: 10.1093/annonc/mdx764.Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2011; 29 (3): 707–714. doi: 10.1093/annonc/mdx764.Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 2005; 11 (1): 89–97. doi: 10.1002/lt.20319.Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 2005; 11 (1): 89–97. doi: 10.1002/lt.20319.Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008; 14 (10): 1428–1436. doi: 10.1002/lt.21475.Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008; 14 (10): 1428–1436. doi: 10.1002/lt.21475.Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005; 80 (2 Suppl): 254–264. doi: 10.1097/01.tp.0000186382.81130.ba.Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005; 80 (2 Suppl): 254–264. doi: 10.1097/01.tp.0000186382.81130.ba.Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998: 147–158. PMID: 10503093.Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998: 147–158. PMID: 10503093.Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89 (7): 1221–1227. doi: 10.1038/sj.bjc.6601219.Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89 (7): 1221–1227. doi: 10.1038/sj.bjc.6601219.Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O’Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl. 2002; 8 (5): 482–487. doi: 10.3748/wjg.v20.i20.617010.Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O’Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl. 2002; 8 (5): 482–487. doi: 10.3748/wjg.v20.i20.617010.Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009; 137 (6): 2010–2017. doi: 10.1053/j.gastro.2009.08.070.Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009; 137 (6): 2010–2017. doi: 10.1053/j.gastro.2009.08.070.Состояние онкологической помощи населению России в 2018 году (ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.Состояние онкологической помощи населению России в 2018 году (ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001; 7 (11): 971–975. doi: 10.4254/wjh.v7.i7.942.Xiol X, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl. 2001; 7 (11): 971–975. doi: 10.4254/wjh.v7.i7.942.Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: de novo neoplasms after liver transplantation. Curr Opin Organ Transplant. 2018; 23 (2): 187–195. doi: 10.1097/MOT.0000000000000499.Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: de novo neoplasms after liver transplantation. Curr Opin Organ Transplant. 2018; 23 (2): 187–195. doi: 10.1097/MOT.0000000000000499.Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009; 9 (10): 2355–2361. doi: 10.4254/wjh.v8.i12.533.Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009; 9 (10): 2355–2361. doi: 10.4254/wjh.v8.i12.533.Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21 (2): 137–148. doi: 10.1016/j.immuni.2004.07.017.Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21 (2): 137–148. doi: 10.1016/j.immuni.2004.07.017.Egeli T, Unek T, Ozbilgin M, Agalar C, Derici S, Akarsu M et al. De novo malignancies after liver transplantation: a single institution experience. Exp Clin Transplant. 2019; 17 (1): 74–78. doi: 10.6002/ect.2017.0111.Egeli T, Unek T, Ozbilgin M, Agalar C, Derici S, Akarsu M et al. De novo malignancies after liver transplantation: a single institution experience. Exp Clin Transplant. 2019; 17 (1): 74–78. doi: 10.6002/ect.2017.0111.Hertig A, Zuckermann A. Rabbit antithymocyte globulin induction and risk of posttransplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. Transpl Immunol. 2015; 32 (3): 179–187. doi: 10.1016/j.trim.2015.04.003.Hertig A, Zuckermann A. Rabbit antithymocyte globulin induction and risk of posttransplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. Transpl Immunol. 2015; 32 (3): 179–187. doi: 10.1016/j.trim.2015.04.003.Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein–Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 23: e13652. doi: 10.1111/ctr.13652. [Epub ahead of print].Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein–Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 23: e13652. doi: 10.1111/ctr.13652. [Epub ahead of print].Doycheva I, Amer S, Watt KD. De novo malignancies after transplantation: risk and surveillance strategies. Med Clin North Am. 2016; 100 (3): 551–567. doi: 10.1016/j.mcna.2016.01.006.Doycheva I, Amer S, Watt KD. De novo malignancies after transplantation: risk and surveillance strategies. Med Clin North Am. 2016; 100 (3): 551–567. doi: 10.1016/j.mcna.2016.01.006.Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol. 2006; 44 (1): 27–32. doi: https://doi.org/10.1016/j.jhep.2005.10.010.Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol. 2006; 44 (1): 27–32. doi: https://doi.org/10.1016/j.jhep.2005.10.010.Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP et al. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol. 2012; 92: 411–415. doi: 10.3748/wjg.v21.i29.8753.Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP et al. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol. 2012; 92: 411–415. doi: 10.3748/wjg.v21.i29.8753.Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004; 18 (4): 446–449. doi: 10.1001/jamadermatol.2015.5548.Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant. 2004; 18 (4): 446–449. doi: 10.1001/jamadermatol.2015.5548.Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11 (8): 1633–1644. doi: 10.1111/j.1600-6143.2011.03573.x.Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11 (8): 1633–1644. doi: 10.1111/j.1600-6143.2011.03573.x.Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87 (2): 233–242. doi: 10.1186/2047-1440-2-S1-S3.Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87 (2): 233–242. doi: 10.1186/2047-1440-2-S1-S3.Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M et al. Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011; 92 (3): 303–310. doi: 10.1097/TP.0b013e3182247ae2.Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M et al. Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011; 92 (3): 303–310. doi: 10.1097/TP.0b013e3182247ae2.De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Precisi A et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation. Transplant Proc. 2018; 50 (10): 3615–3620. doi: 10.1016/j.transproceed.2018.07.011.De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Precisi A et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation. Transplant Proc. 2018; 50 (10): 3615–3620. doi: 10.1016/j.transproceed.2018.07.011.

The authors declare that there are no conflicts of interest present.